TY - JOUR
T1 - Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers
T2 - A Reappraisal
AU - the Hereditary Breast Cancer Clinical Study Group
AU - Kotsopoulos, Joanne
AU - Lubinski, Jan
AU - Gronwald, Jacek
AU - Menkiszak, Janusz
AU - McCuaig, Jeanna
AU - Metcalfe, Kelly
AU - Foulkes, William D.
AU - Neuhausen, Susan L.
AU - Sun, Sophie
AU - Karlan, Beth Y.
AU - Eisen, Andrea
AU - Tung, Nadine
AU - Olopade, Olufunmilayo I.
AU - Couch, Fergus J.
AU - Huzarski, Tomasz
AU - Senter, Leigha
AU - Bordeleau, Louise
AU - Singer, Christian F.
AU - Eng, Charis
AU - Fruscio, Robert
AU - Pal, Tuya
AU - Sun, Ping
AU - Narod, Steven A.
AU - Cybulski, Cezary
AU - Rosen, Barry
AU - Sweet, Kevin
AU - Zakalik, Dana
AU - Wood, Marie
AU - McKinnon, Wendy
AU - Elser, Christine
AU - Wiesner, Georgia
AU - Friedman, Eitan
AU - Meschino, Wendy
AU - Snyder, Carrie
AU - Poll, Aletta
AU - Warner, Ellen
AU - Kim, Raymond
AU - Armel, Susan
AU - Ainsworth, Peter
AU - Steele, Linda
AU - Saal, Howard
AU - Serfas, Kim
AU - Panchal, Seema
AU - Gruber, Stephen
AU - Cullinane, Carey A.
AU - Reilly, Robert E.
AU - Blum, Joanne L.
AU - Kwong, Ava
AU - Rayson, Daniel
AU - Mercer, Leanne
N1 - Funding Information:
We are grateful for the contributions of the women who participated in this study, without whom this research would not be possible. We acknowledge the study staff, students, and volunteers who assisted with data collection and data entry: Ellen MacDougall, Shana Kim, ClotildeNgwa, Aiman Syeda, Anasua Kundu, Nurun Nahar, Abigail Sims, Alexandra Parco, Christine Zhu, Cindy Zhang, Elizabeth Hall, Lisa Asbroek, Rebecca Raj, Shaelyn Laurie, Kamrun Urmi, Amina Mahmood, Mayra Gholizadeh, Nazia Awan, Neelam Dehal, Pooja Chaudhary, Pooja Patel, Yasmin Tehrani, Seetha Venkatewsaran, Seema Mehta, Jasdeep Brar, and Marsela Supriadi. This work was supported by a Canadian Cancer Society Research Institute grant (S.L. Neuhausen; 703058); the Canadian Institutes of Health Research (S.L. Neuhausen and J. Kotsopoulos; FDN154275); and the PeterGilgan Center forWomen's Cancers at Women's College Hospital, in partnership with the Canadian Cancer Society (J. Kotsopoulos and S.L. Neuhausen). Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair.
Funding Information:
This work was supported by a Canadian Cancer Society Research Institute grant (S.L. Neuhausen; 703058); the Canadian Institutes of Health Research (S.L. Neuhausen and J. Kotsopoulos; FDN 154275); and the Peter Gilgan Center for Women’s Cancers at Women’s College Hospital, in partnership with the Canadian Cancer Society (J. Kotsopoulos and S.L. Neuhausen). Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair.
Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/7
Y1 - 2022/7
N2 - Background: The lack of consensus on whether bilateral oophorectomy impacts risk of developing breast cancer among BRCA1 mutation carriers might be attributed to various biases, specifically, cancer-induced testing bias due to inclusion of prevalent cases. We conducted two complementary matched case-control analyses to evaluate the association of oophorectomy and BRCA1 breast cancer. Methods: A research questionnaire was administered every two years to collect information on exposures and disease. In the first analysis, we limited the study to prevalent breast cancer cases (diagnosed prior to study entry; n = 2,962) who were matched to controls on year of birth and country of residence (n=4,358). In the second approach, we limited to 330 incident cases (diagnosed in the follow-up period) and 1,548 matched controls. Conditional logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) of invasive breast cancer. Results: In the first approach, there was a significant inverse association between oophorectomy and the risk of developing breast cancer [OR = 0.43; 95% confidence interval (CI), 0.34- 0.55; P < 00001]. In the second approach, there was no association between oophorectomy and risk (OR = 1.21; 95% CI, 0.87-1.70; P = 0.26). Conclusions: The inclusion of women with a personal history of breast cancer prior to ascertainment likely impacts upon the association of oophorectomy and BRCA1 breast cancer risk. Impact: Oophorectomy is unlikely a determinant of breast cancer risk in BRCA1 mutation carriers but should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.
AB - Background: The lack of consensus on whether bilateral oophorectomy impacts risk of developing breast cancer among BRCA1 mutation carriers might be attributed to various biases, specifically, cancer-induced testing bias due to inclusion of prevalent cases. We conducted two complementary matched case-control analyses to evaluate the association of oophorectomy and BRCA1 breast cancer. Methods: A research questionnaire was administered every two years to collect information on exposures and disease. In the first analysis, we limited the study to prevalent breast cancer cases (diagnosed prior to study entry; n = 2,962) who were matched to controls on year of birth and country of residence (n=4,358). In the second approach, we limited to 330 incident cases (diagnosed in the follow-up period) and 1,548 matched controls. Conditional logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) of invasive breast cancer. Results: In the first approach, there was a significant inverse association between oophorectomy and the risk of developing breast cancer [OR = 0.43; 95% confidence interval (CI), 0.34- 0.55; P < 00001]. In the second approach, there was no association between oophorectomy and risk (OR = 1.21; 95% CI, 0.87-1.70; P = 0.26). Conclusions: The inclusion of women with a personal history of breast cancer prior to ascertainment likely impacts upon the association of oophorectomy and BRCA1 breast cancer risk. Impact: Oophorectomy is unlikely a determinant of breast cancer risk in BRCA1 mutation carriers but should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.
UR - http://www.scopus.com/inward/record.url?scp=85133980954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133980954&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-1196
DO - 10.1158/1055-9965.EPI-21-1196
M3 - Article
C2 - 35477169
AN - SCOPUS:85133980954
SN - 1055-9965
VL - 31
SP - 1351
EP - 1358
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 7
ER -